Increasing Awareness and Understanding of Amyloid Transthyretin Cardiomyopathy (ATTR-CM)

    From Pfizer, Inc.

    The funder's mission is to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and education for healthcare professionals in Latin America.

    Type of Support

    Overview

    This grant program focuses on encouraging organizations to propose educational activities aimed at healthcare professionals. The goal is to improve the identification, suspicion, diagnosis, and treatment of heart failure patients at risk for Transthyretin (TTR) Amyloidosis. It emphasizes the need for increased awareness among healthcare professionals to recognize heart failure patients who might be at risk for TTR Amyloidosis and advocates for an evidence-based approach to facilitate early and appropriate patient identification.

    Eligibility

    Organization's Location
    irure culpa
    Program Location
    consectetur
    Organization Type
    up to 100k

    Submission

    Visit Apply for more information.

    Similar grants